Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-06-27
2006-06-27
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S275000
Reexamination Certificate
active
07067665
ABSTRACT:
The present invention relates to compounds comprising the following formula:in-line-formulae description="In-line Formulae" end="lead"?R0-Q-X-Q′-W-U-V-G-M (I)in-line-formulae description="In-line Formulae" end="tail"?These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.
REFERENCES:
patent: 4309212 (1982-01-01), Takemoto et al.
patent: 4428874 (1984-01-01), Svendsen
patent: 4568636 (1986-02-01), Svendsen
patent: 5753659 (1998-05-01), Mills
patent: 0019589 (1980-11-01), None
patent: 2011892 (1979-07-01), None
patent: 00/59893 (2000-10-01), None
Nomoto et al, Chem. Pharm. Bull., 38(11), 3014-3019, 1990.
Baiey, et al.,Angewandte Chemie, 39: 506-508;(2000).
Campillo, et al.,Journal Medicinal Chemistry, 42: 3279-3288 (1999).
Choi-Stedeski, et al., Bioorganic and Medicinal Chemistry Letters, 9: 2539-2544 (1999).
European Search report dated Oct. 29, 2001, foir European Patent Application No. 00/128477.
Fujio, et al.,Bloorganic and Medicinal Chemistry Letters, 10: 2457-2481 (2000).
Hanessian, et al.,Bloorganic and Medicinal Chemistry Letters, 10; 243-247 (2000).
He, et al.,Bioorganic and Medicinal Chemistry Letters, 10: 1737-1739 (2000).
Herron, et al.,J. Med. Chem.,43: 859-872 (2000).
Hoekstra, et al.,J. Med. Chem.,42: 5254-5285 (1999).
Maignan, et al.,J. Med. Chem.,43: 3226-3232 (2000).
Ogino, et al,Bioorganic and Medicinal Chemistry Letters, 8:75-80 (1998).
Okade, et al.,Bioorganic and Medicinal Chemistry Letters, 10: 2217-2221 (2000).
Pitts, et al.,J. Med. Chem.,43: 27-40 (2000).
Rehse, et al.,Archiv der Pharmazie, 333: 157-161 (2000).
Roussel, et al.,Tetrahedron, 55; 6219-6230 (1999).
Walser, et al.,J. Med. Chem.,34; 1209-1221 (1991).
Gerlach Uwe
Matter Hans
Nazare Marc
Peyman Anuschirwan
Will David William
Kumar Shailendra
Rossi Joseph D.
Sanofi-Aventis Deutschland GmbH
LandOfFree
Oxybenzamide derivatives useful for inhibiting factor Xa or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxybenzamide derivatives useful for inhibiting factor Xa or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxybenzamide derivatives useful for inhibiting factor Xa or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676585